Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients No dose-limiting toxicities reported in first or second cohorts (n=6) The dosing of patients on dose levels one and two marks the midway pointContinue reading “Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients”
Press Release Archives
Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy
Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy Patented technology allows for manufacturing hundreds of therapeutic doses of Killer T cells (Cytotoxic CD8+ T Lymphocytes) from a single donor Tevogen’s investigational T cell therapy, TVGN-489, is designed to detect targetsContinue reading “Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy”
Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council
Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council January 5, 2022 METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company, announces the appointment of Sten H. Vermund, M.D., Ph.D., Dean andContinue reading “Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council”